Key facts
- Laron syndrome, characterized by short stature due to growth hormone insensitivity, is prevalent in southern Ecuador.
- Individuals with Laron syndrome exhibit a significantly lower incidence of cancer and diabetes compared to the general population.
- Research suggests that lower levels of Insulin-like Growth Factor 1 (IGF-1) are linked to this reduced disease risk.
- Scientists aim to develop treatments that mimic the syndrome's protective effects.
- A new study by Prof. Zvi Laron will detail all known cases of the mutation.
In the remote town of Piñas, Ecuador, a rare genetic condition known as Laron syndrome affects an unusually high number of residents. This syndrome prevents the body from growing taller than approximately 1.2 meters (3.9 feet) due to an inability to properly utilize growth hormone. Despite the challenges associated with their condition, individuals like twin sisters María Luísa and María del Cisne find strength in their shared experiences and community support.
Beyond the physical implications, researchers are investigating a potential health benefit associated with Laron syndrome: a lower incidence of diseases such as cancer and diabetes compared to the general population. Endocrinologist Dr. Jaime Guevara, who has studied the syndrome for decades, hypothesizes that the low levels of Insulin-like Growth Factor 1 (IGF-1) in patients with Laron syndrome may be responsible for this protective effect. The theory is that IGF-1 plays a role in preventing cancer cells from undergoing apoptosis (programmed cell death), and lower IGF-1 levels could therefore reduce cancer risk.
This research holds promise for developing new preventative treatments. The goal is to replicate the syndrome's effects through drugs or dietary changes in individuals without Laron syndrome. Prof. Zvi Laron, who first identified the condition 60 years ago, is also documenting known cases and has observed potential cancer protection in his patients. His upcoming research paper aims to provide exact numbers and details on growth hormone receptor defects.
While the findings offer hope, the reality for patients can be complex. The twins' experience highlights the social challenges, particularly when moving to areas where short stature is uncommon. Furthermore, a recent diagnosis of colon cancer in María del Cisne served as a stark reminder that individuals with Laron syndrome are not entirely immune to diseases, underscoring the importance of self-care and ongoing medical attention. The drug Increlex, which can aid growth, exists but is costly and has limitations, making access difficult for some.